Reprogramming the tumormicroenvironment to improve immunotherapy of glioblastoma

重新编程肿瘤微环境以改善胶质母细胞瘤的免疫治疗

基本信息

  • 批准号:
    10417806
  • 负责人:
  • 金额:
    $ 37.96万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-04-01 至 2027-03-31
  • 项目状态:
    未结题

项目摘要

Glioblastoma (GBM) is a uniformly fatal malignancy with limited treatment options. Immune checkpoint blockers (ICBs) have revolutionized the treatment of several malignancies, but have failed in all Phase III trials in newly diagnosed and recurrent glioblastoma (GBM) patients. This limited efficacy of ICBs is due to profound immunosuppression in the GBM tumor microenvironment (TME) caused by paucity of cytotoxic T cells, abundance of regulatory T cells, resident macrophages and microglia and infiltration of myeloid- derived cells from the bone marrow. Wnt signaling fuels GBM progression by aiding proliferation, stemness, epithelial-to-mesenchymal transition and chemoresistance. However, the role of Wnt signaling in immune suppression in GBM is not known. In our preliminary studies we found that Wnt signaling is elevated in murine and human GBMs. A porcupine inhibitor WNT974 -- that blocks Wnt signaling -- in combination with anti-PD-1 antibody (αPD1) prolonged the survival of GBM-bearing mice. This increased survival was accompanied by an expansion of a novel DC3-like dendritic cell state and decrease in granulocytic myeloid- derived suppressor cells (gMDSCs) that may mediate the response to this combination in responding tumors. By contrast, poorly-responding tumors showed an increase in monocytic (m) MDSCs, insufficient T cell infiltration and T cell effector function, suggesting potential resistance mechanisms. Our prior work shows that genetic deletion or pharmacological inhibition of Wnt signaling disrupts the GBM vasculature and makes it leaky. Moreover, ICBs themselves increase edema in GBM patients and require the use of steroids that are highly immunosuppressive. Our preliminary studies show that losartan, an angiotensin receptor blocker, can reduce αPD1-induced edema and reprogram the immunosuppressive TME to an immunostimulatory milieu to favor T cell infiltration and effector function. Building on these exciting findings, our overarching hypothesis is that Wnt signaling reprograms the GBM tumor microenvironment from immune suppressive to immune stimulatory, thus potentiating αPD1 therapy, and adding losartan further enhances the outcome by overcoming treatment resistance mechanisms, and reducing edema. We will test this hypothesis by examining the function of (a) antigen cross-presenting DCs and (b) decreased gMDSCs in mediating the response to WNT974 and αPD1 (Aim 1). We will also test the hypothesis that resistance to WNT974+αPD1 is caused by (a) increased mMDSCs and (b) lack of T cell infiltration and function (Aim 2). In Aim 3, we will test the hypothesis that the combination of losartan with Wnt-inhibition and αPD1 will (a) reduce mMDSCs infiltration and increase T cell infiltration and effector function and (b) alleviate edema and provide durable responses in GBMs that are refractory to WNT974+αPD1. If successful, our results will inform the design of future GBM clinical trials to improve the outcome of ICBs using agents currently in clinical trials for non-CNS tumors (WNT974: e.g., NCT01351103; and losartan: NCT03563248).
胶质母细胞瘤(GBM)是一种致命的恶性肿瘤,治疗方案有限。免疫检查点

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Rakesh K. Jain其他文献

In vitro and in vivo quantification of adhesion between leukocytes and vascular endothelium.
白细胞和血管内皮之间粘附的体外和体内定量。
  • DOI:
    10.1385/0-89603-516-6:553
  • 发表时间:
    1999
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Rakesh K. Jain;L. Munn;D. Fukumura;R. Melder
  • 通讯作者:
    R. Melder
Leveraging insights from cancer to improve tuberculosis therapy
利用癌症研究的见解来改进结核病治疗
  • DOI:
    10.1016/j.molmed.2024.07.011
  • 发表时间:
    2025-01-01
  • 期刊:
  • 影响因子:
    13.800
  • 作者:
    Meenal Datta;Laura E. Via;Véronique Dartois;Lei Xu;Clifton E. Barry;Rakesh K. Jain
  • 通讯作者:
    Rakesh K. Jain
Xanthan gum: an economical substitute for agar in plant tissue culture media
黄原胶:植物组织培养基中琼脂的经济替代品
  • DOI:
  • 发表时间:
    2006
  • 期刊:
  • 影响因子:
    6.2
  • 作者:
    Rakesh K. Jain;S. Babbar
  • 通讯作者:
    S. Babbar
Anaerobes in bacterial vaginosis.
细菌性阴道病中的厌氧菌。
Using mathematical modelling and AI to improve delivery and efficacy of therapies in cancer
利用数学建模和人工智能提高癌症治疗的递送和疗效
  • DOI:
    10.1038/s41568-025-00796-w
  • 发表时间:
    2025-02-19
  • 期刊:
  • 影响因子:
    66.800
  • 作者:
    Constantinos Harkos;Andreas G. Hadjigeorgiou;Chrysovalantis Voutouri;Ashwin S. Kumar;Triantafyllos Stylianopoulos;Rakesh K. Jain
  • 通讯作者:
    Rakesh K. Jain

Rakesh K. Jain的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Rakesh K. Jain', 18)}}的其他基金

Reprogramming the tumormicroenvironment to improve immunotherapy of glioblastoma
重新编程肿瘤微环境以改善胶质母细胞瘤的免疫治疗
  • 批准号:
    10595045
  • 财政年份:
    2022
  • 资助金额:
    $ 37.96万
  • 项目类别:
Improving treatment of HER2+ breast cancer brain metastasis by targeting lipid metabolism
通过靶向脂质代谢改善 HER2 乳腺癌脑转移的治疗
  • 批准号:
    10185953
  • 财政年份:
    2021
  • 资助金额:
    $ 37.96万
  • 项目类别:
Improving treatment of HER2+ breast cancer brain metastasis by targeting lipid metabolism
通过靶向脂质代谢改善 HER2 乳腺癌脑转移的治疗
  • 批准号:
    10397627
  • 财政年份:
    2021
  • 资助金额:
    $ 37.96万
  • 项目类别:
Improving treatment of HER2+ breast cancer brain metastasis by targeting lipid metabolism
通过靶向脂质代谢改善 HER2 乳腺癌脑转移的治疗
  • 批准号:
    10620649
  • 财政年份:
    2021
  • 资助金额:
    $ 37.96万
  • 项目类别:
Targeting physical stress-driven mechanisms to overcome glioblastoma treatment resistance
针对物理压力驱动机制克服胶质母细胞瘤治疗耐药性
  • 批准号:
    10696949
  • 财政年份:
    2021
  • 资助金额:
    $ 37.96万
  • 项目类别:
Targeting physical stress-driven mechanisms to overcome glioblastoma treatment resistance
针对物理压力驱动机制克服胶质母细胞瘤治疗耐药性
  • 批准号:
    10273309
  • 财政年份:
    2021
  • 资助金额:
    $ 37.96万
  • 项目类别:
Improving treatment of brain metastases from HER2-positive breast cancer
改善 HER2 阳性乳腺癌脑转移的治疗
  • 批准号:
    8864389
  • 财政年份:
    2015
  • 资助金额:
    $ 37.96万
  • 项目类别:
Dissecting Pediatric Brain Tumor Microenvironment to Improve Treatment
剖析小儿脑肿瘤微环境以改善治疗
  • 批准号:
    9334783
  • 财政年份:
    2015
  • 资助金额:
    $ 37.96万
  • 项目类别:
Dissecting Pediatric Brain Tumor Microenvironment to Improve Treatment
剖析小儿脑肿瘤微环境以改善治疗
  • 批准号:
    9766197
  • 财政年份:
    2015
  • 资助金额:
    $ 37.96万
  • 项目类别:
Overcoming Resistance to Anti-VEGF Treatment of Glioblastoma
克服胶质母细胞瘤抗 VEGF 治疗的耐药性
  • 批准号:
    8463131
  • 财政年份:
    2013
  • 资助金额:
    $ 37.96万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 37.96万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 37.96万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 37.96万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 37.96万
  • 项目类别:
    Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 37.96万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 37.96万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 37.96万
  • 项目类别:
    Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
  • 批准号:
    10699504
  • 财政年份:
    2023
  • 资助金额:
    $ 37.96万
  • 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
  • 批准号:
    10491642
  • 财政年份:
    2023
  • 资助金额:
    $ 37.96万
  • 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
  • 批准号:
    10782567
  • 财政年份:
    2023
  • 资助金额:
    $ 37.96万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了